Demand For Cystic Fibrosis Drugs Will Drive CFTR Modulators Market Says Kuick Research NEW DELHI, April 22, 2021 /PRNewswire/ -- "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

The MarketWatch News Department was not involved in the creation of this content. Cystic Fibrosis Therapeutics Market Set to Reach USD 35.09 Billion by 2033 as Precision CFTR Modulator Therapies ...

Please provide your email address to receive an email when new articles are posted on . Patients from minority racial and ethnic groups with cystic fibrosis are less likely to be eligible for cystic ...

Please provide your email address to receive an email when new articles are posted on . Triple therapy improved lung function, BMI and other factors. Patients naïve to cystic fibrosis transmembrane ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application for VX ...

If approved, gene therapies could fill gaps in patient care left by CFTR modulators, notes GD Healthcare analyst, Vinie Varkey.

- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene ...

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.

AUSTIN, Texas and TOKYO, Dec. 1, 2025 /PRNewswire/ --According to DataM Intelligence, the Cystic Fibrosis (CF) Therapeutics Market Size accelerated to USD 10.60 billion in 2024, up from USD 9.22 ...

Sionna Therapeutics, Inc. announced that preclinical data on its novel cystic fibrosis (CF) treatment candidates, SION-451 and SION-719, will be presented at the European Cystic Fibrosis Society’s ...